GSK’s (GSK) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their underweight rating on shares of GSK (LON:GSK) in a research report sent to investors on Friday, MarketBeat reports.

Separately, Berenberg Bank dropped their target price on shares of GSK from GBX 1,820 ($23.53) to GBX 1,600 ($20.69) and set a “buy” rating on the stock in a report on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.35).

GSK Stock Up 0.6 %

Shares of GSK stock opened at GBX 1,486.08 ($19.21) on Friday. GSK has a 1 year low of GBX 1,282.50 ($16.58) and a 1 year high of GBX 1,823.50 ($23.58). The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The business’s fifty day moving average is GBX 1,456.03 and its 200-day moving average is GBX 1,431.41. The stock has a market cap of £60.30 billion, a PE ratio of 24.01, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Buying and Selling at GSK

In other news, insider Emma Walmsley sold 120,653 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.79), for a total value of £1,753,088.09 ($2,266,728.85). Also, insider Wendy Becker purchased 536 shares of the stock in a transaction dated Thursday, March 20th. The shares were acquired at an average price of GBX 1,515 ($19.59) per share, for a total transaction of £8,120.40 ($10,499.61). Insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.